Sign in
Stories
AbbVie's Healthcare Acquisitions
Share
BioPharma Shift: Coherus-Sandoz Acquisit...
Biotech Downturn and Funding Challenges
Biotech Funding Challenges and IPO Droug...
Amgen's Weight-Loss Drugs Market Entranc...
Analyst Recommendations Impact Diverse C...
Avid Bioservices Financial Turmoil
Overview
API
AbbVie's strategic acquisitions of ImmunoGen and Cerevel Therapeutics for $10.1 billion and $8.7 billion respectively, aim to strengthen its cancer and neurology pipelines, reflecting a focus on mid-size deals for future growth.
Ask a question
How do these acquisitions align with AbbVie's overall growth strategy for the 2030s?
How might AbbVie's acquisitions impact the competitive landscape in the cancer and neurology sectors?
What are the potential risks and benefits associated with AbbVie's focus on mid-size deals?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Coverage